Year: 2020
Type: review
Abstract: Individuals who are diagnosed with amyotrophic lateral sclerosis (ALS) today face the same historically intransigent problem that has existed since the initial description of the disease in the 1860s — a lack of effective therapies. In part, the development of new treatments has been hampered by an imperfect understanding of the biological processes that trigger ALS and promote disease progression. Advances in our understanding of these biological processes, including the causative genetic mutations, and of the influence of environmental factors have deepened our appreciation of disease pathophysiology. The consequent identification of pathogenic targets means that the introduction of effective therapies is becoming a realistic prospect. Progress in precision medicine, including genetically targeted therapies, will undoubtedly change the natural history of ALS. The evolution of clinical trial designs combined with improved methods for patient stratification will facilitate the translation of novel therapies into the clinic. In addition, the refinement of emerging biomarkers of therapeutic benefits is critical to the streamlining of care for individuals. In this Review, we synthesize these developments in ALS and discuss the further developments and refinements needed to accelerate the introduction of effective therapeutic approaches. The identification of pathogenic targets in amyotrophic lateral sclerosis means that effective therapies are increasingly likely. In this Review, Kiernan et al. discuss advances towards therapy and the innovations needed in clinical trials to facilitate the translation into treatments for patients.
Source: Nature Reviews Neurology
Institutions: The University of Sydney, Royal Prince Alfred Hospital, University of Oxford, NIHR Sheffield Biomedical Research Centre, University of Sheffield, Trinity College Dublin, Beaumont Hospital, Creighton University, Barrow Neurological Institute, University of Arizona College of Medicine- Phoenix, King's College London, Harvard University, Massachusetts General Hospital, Barwon Health, University Medical Center Utrecht
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Funders: AstraZeneca, South London and Maudsley NHS Foundation Trust, Wellcome Trust, EU Joint Programme – Neurodegenerative Disease Research, National Institute for Health and Care Research, Motor Neurone Disease Association, King's College London, Medical Research Council, National Health and Medical Research Council
Awards: G1844089555, G244218419, JPND Biological Resource Analysis to Identify New MEchanisms and phenotypes in Neurodegenerative Diseases (BRAIN-MEND), Developing new therapies for neurodegeneration and dementia, G4657563902, A Randomised Double-Blind Placebo-Controlled Phase 3 Trial Of Triumeq In Amyotrophic Lateral Sclerosis, STRENGTH, Frontotemporal dementia and motor neurodegenerative syndromes, Motor Neurone Disease: Patient centred care for a progressive neurological disease - evidence driving policy., Non-Alzheimer’s disease degenerative dementias: Identifying prodromal genetic/familial phenotypes, modifying factors, and protein variations involved in progression
OpenAlex ID: W3115439136
